The drug of high metabolic activity Kokarnit in the treatment of diabetic autonomic neuropathy of the heart

Authors: S. V. Popov, O. K. Melekhovets, N. V. Demikhova, L. B. Vynnychenko

Sumy state university, medical institute


Summary

Left ventricular diastolic dysfunction in patients with diabetes is formed in the absence of atherosclerotic changes as a consequence of diabetic cardiac autonomic neuropathy in the early stages of diabetes. Progression of autonomic cardiac neuropathy in cardio-vascular type is associated with the violation of energy supply of cells, protein synthesis, electrolyte exchange, the exchange of trace elements, oxidation reduction processes, oxygen-transport function of blood, so that metabolic therapy is carried out to optimize the processes of formation and energy costs. The drug cocarnit activates processes of aerobic oxidation of glucose, as well as providing regulatory influence on the oxidation of fatty acids. Applying of cocarnit in complex therapy in patients with diabetic cardiac autonomic neuropathy found improvement of left ventricular diastolic function, and positive dynamics in the efferent activity balance of the sympathetic and parasympathetic control of heart rate variability, which provides the regression of clinical symptoms.

Key words: diabetic cardiac autonomic neuropathy, left ventricular diastolic dysfunction, metabolic therapy, cocarnit.

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design